LAE 118
Alternative Names: LAE-118Latest Information Update: 20 Oct 2023
At a glance
- Originator Laekna Therapeutics
- Class Antineoplastics
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 31 Aug 2023 LAE 118 is available for licensing as of 31 Aug 2023. http://360storage.hkej.com/ipo/02105.pdf
- 31 Aug 2023 Early research in Cancer in China (unspecified route) (Laekna Therapeutics pipeline, August 2023)
- 16 Jun 2023 Laekna Therapeutics announces intention to submit IND to US FDA or NMPA for Cancer by 2025